ProPublica

Journalism in the Public Interest

Cancel

Prescriber Checkup

Prescriber Checkup » Illinois » Hematology Oncology

Top Hematology Oncology Prescribers in Illinois

Top Prescribers

Providers are grouped by the primary specialty they listed when applying for a national health ID number. This doesn’t necessarily mean the person has special training or certification. Specialty is self-reported by providers and may have changed. Patients and claims shown are for Medicare Part D only.

Prescriber Claims Filled Total Cost Medicare Part D Patients Claims for Brand Name Drugs Schedule Two Schedule Three Dangerous Drugs to Seniors Brand Name Drugs Prescription Price
DOMINIC HO M.D.

Hematology Oncology

6,711

$604K

394
355 are 65+

3%
patients receiving schedule two controlled substances

Avg: 9%

9%
patients receiving schedule three controlled substances

Avg: 13%

2%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 1%

27%
prescriptions for brand name drugs

Avg: 17%

$90
Average prescription price

Avg: $345

YAGNESH OZA M.D.

Hematology Oncology

3,715

$748K

318
287 are 65+

9%
patients receiving schedule two controlled substances

Avg: 9%

12%
patients receiving schedule three controlled substances

Avg: 13%

3%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 1%

18%
prescriptions for brand name drugs

Avg: 17%

$201
Average prescription price

Avg: $345

JAGDISH SHAH MD

Hematology Oncology

3,476

$77.9K

190
110 are 65+

0%
patients receiving schedule two controlled substances

Avg: 9%

22%
patients receiving schedule three controlled substances

Avg: 13%

3%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 1%

22%
prescriptions for brand name drugs

Avg: 17%

$22
Average prescription price

Avg: $345

MICHAEL VEEDER MD

Hematology Oncology

3,145

$650K

358
294 are 65+

18%
patients receiving schedule two controlled substances

Avg: 9%

22%
patients receiving schedule three controlled substances

Avg: 13%

1%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 1%

16%
prescriptions for brand name drugs

Avg: 17%

$207
Average prescription price

Avg: $345

MANJEET CHAWLA MD

Hematology Oncology

2,842

$434K

260
181 are 65+

5%
patients receiving schedule two controlled substances

Avg: 9%

23%
patients receiving schedule three controlled substances

Avg: 13%

3%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 1%

21%
prescriptions for brand name drugs

Avg: 17%

$153
Average prescription price

Avg: $345

CHRISTOPHER ROSE M.D.

Hematology Oncology

2,731

$450K

257
244 are 65+

0%
patients receiving schedule two controlled substances

Avg: 9%

12%
patients receiving schedule three controlled substances

Avg: 13%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 1%

26%
prescriptions for brand name drugs

Avg: 17%

$165
Average prescription price

Avg: $345

RODNEY NELSON M.D.

Hematology Oncology

2,699

$312K

199
183 are 65+

0%
patients receiving schedule two controlled substances

Avg: 9%

12%
patients receiving schedule three controlled substances

Avg: 13%

1%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 1%

14%
prescriptions for brand name drugs

Avg: 17%

$116
Average prescription price

Avg: $345

JOHN VISCONTI D.O.

Hematology Oncology

2,503

$1.02M

264
201 are 65+

14%
patients receiving schedule two controlled substances

Avg: 9%

15%
patients receiving schedule three controlled substances

Avg: 13%

3%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 1%

16%
prescriptions for brand name drugs

Avg: 17%

$407
Average prescription price

Avg: $345

NGUYET LE-LINDQUISTER MD

Hematology Oncology

2,361

$444K

289
221 are 65+

14%
patients receiving schedule two controlled substances

Avg: 9%

13%
patients receiving schedule three controlled substances

Avg: 13%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 1%

12%
prescriptions for brand name drugs

Avg: 17%

$188
Average prescription price

Avg: $345

YUNUS NOMANBHOY M.D.

Hematology Oncology

2,248

$427K

215
185 are 65+

7%
patients receiving schedule two controlled substances

Avg: 9%

20%
patients receiving schedule three controlled substances

Avg: 13%

2%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 1%

18%
prescriptions for brand name drugs

Avg: 17%

$190
Average prescription price

Avg: $345

PAUL FISHKIN MD

Hematology Oncology

2,205

$986K

244
199 are 65+

15%
patients receiving schedule two controlled substances

Avg: 9%

26%
patients receiving schedule three controlled substances

Avg: 13%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 1%

14%
prescriptions for brand name drugs

Avg: 17%

$447
Average prescription price

Avg: $345

MIR ALIKHAN M.D.

Hematology Oncology

2,158

$862K

235
202 are 65+

11%
patients receiving schedule two controlled substances

Avg: 9%

9%
patients receiving schedule three controlled substances

Avg: 13%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 1%

12%
prescriptions for brand name drugs

Avg: 17%

$399
Average prescription price

Avg: $345

RASHEED AKHTAR M.D.

Hematology Oncology

2,123

$120K

181
137 are 65+

0%
patients receiving schedule two controlled substances

Avg: 9%

11%
patients receiving schedule three controlled substances

Avg: 13%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 1%

28%
prescriptions for brand name drugs

Avg: 17%

$57
Average prescription price

Avg: $345

JAMES KNOST MD

Hematology Oncology

2,115

$624K

224
191 are 65+

17%
patients receiving schedule two controlled substances

Avg: 9%

17%
patients receiving schedule three controlled substances

Avg: 13%

3%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 1%

14%
prescriptions for brand name drugs

Avg: 17%

$295
Average prescription price

Avg: $345

DOLORES ESTRADA MD

Hematology Oncology

2,092

$376K

194
153 are 65+

19%
patients receiving schedule two controlled substances

Avg: 9%

24%
patients receiving schedule three controlled substances

Avg: 13%

1%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 1%

17%
prescriptions for brand name drugs

Avg: 17%

$180
Average prescription price

Avg: $345

DIANE PRAGER MD

Hematology Oncology

1,967

$274K

259
222 are 65+

10%
patients receiving schedule two controlled substances

Avg: 9%

10%
patients receiving schedule three controlled substances

Avg: 13%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 1%

8%
prescriptions for brand name drugs

Avg: 17%

$139
Average prescription price

Avg: $345

SESHAN SUBRAMANIAN MD

Hematology Oncology

1,910

$459K

182
152 are 65+

8%
patients receiving schedule two controlled substances

Avg: 9%

13%
patients receiving schedule three controlled substances

Avg: 13%

1%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 1%

23%
prescriptions for brand name drugs

Avg: 17%

$240
Average prescription price

Avg: $345

LEONARD KLEIN

Hematology Oncology

1,893

$839K

157
136 are 65+

9%
patients receiving schedule two controlled substances

Avg: 9%

12%
patients receiving schedule three controlled substances

Avg: 13%

2%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 1%

27%
prescriptions for brand name drugs

Avg: 17%

$443
Average prescription price

Avg: $345

BENJAMIN ESPARAZ M.D.

Hematology Oncology

1,840

$354K

238
212 are 65+

11%
patients receiving schedule two controlled substances

Avg: 9%

15%
patients receiving schedule three controlled substances

Avg: 13%

1%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 1%

11%
prescriptions for brand name drugs

Avg: 17%

$193
Average prescription price

Avg: $345

SYED ZAHIR MD

Hematology Oncology

1,830

$522K

231
194 are 65+

16%
patients receiving schedule two controlled substances

Avg: 9%

17%
patients receiving schedule three controlled substances

Avg: 13%

1%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 1%

14%
prescriptions for brand name drugs

Avg: 17%

$285
Average prescription price

Avg: $345

JAMES EGNER MD

Hematology Oncology

1,799

$592K

145
118 are 65+

12%
patients receiving schedule two controlled substances

Avg: 9%

19%
patients receiving schedule three controlled substances

Avg: 13%

2%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 1%

19%
prescriptions for brand name drugs

Avg: 17%

$329
Average prescription price

Avg: $345

MUHAMMAD ALI M.D

Hematology Oncology

1,759

$469K

299
237 are 65+

17%
patients receiving schedule two controlled substances

Avg: 9%

7%
patients receiving schedule three controlled substances

Avg: 13%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 1%

14%
prescriptions for brand name drugs

Avg: 17%

$266
Average prescription price

Avg: $345

GREGORY GERSTNER M.D.

Hematology Oncology

1,712

$1.05M

201
160 are 65+

14%
patients receiving schedule two controlled substances

Avg: 9%

20%
patients receiving schedule three controlled substances

Avg: 13%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 1%

18%
prescriptions for brand name drugs

Avg: 17%

$615
Average prescription price

Avg: $345

MARK WOODSON MD

Hematology Oncology

1,625

$639K

224
177 are 65+

18%
patients receiving schedule two controlled substances

Avg: 9%

17%
patients receiving schedule three controlled substances

Avg: 13%

3%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 1%

18%
prescriptions for brand name drugs

Avg: 17%

$393
Average prescription price

Avg: $345

ALEXANDER HANTEL MD

Hematology Oncology

1,621

$556K

203
179 are 65+

10%
patients receiving schedule two controlled substances

Avg: 9%

9%
patients receiving schedule three controlled substances

Avg: 13%

1%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 1%

15%
prescriptions for brand name drugs

Avg: 17%

$343
Average prescription price

Avg: $345

Sources

Centers for Medicare and Medicaid Services; National Technical Information Service; First Databank